search
Back to results

Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health

Primary Purpose

Cognitive Performance, Memory, Mood

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Muscadine Wine Polyphenol
Placebo
Sponsored by
University of Florida
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cognitive Performance

Eligibility Criteria

50 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy
  • BMI (18.5-29.9)
  • Body weight ≥110 pounds

Exclusion Criteria:

  • Pregnancy
  • Breast-feeding
  • Smokers
  • Diabetic
  • Heavy drinkers
  • Subjective but not clinically diagnosed cognitive impairment (Montreal cognitive assessment score <26),
  • Inability to understand the cognitive function tasks
  • Intake of medication that might influence the outcome of the study (e.g. psychosimulant)
  • Clinically diagnosed mental illnesses
  • Cardiovascular and neurological disorders

Sites / Locations

  • Food Science and human nutrition department at University of FloridaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Intervention-Placebo

Placebo-Intervention

Arm Description

Participants in this arm will consume muscadine wine polyphenol for six weeks and then placebo for another six weeks. The two phases are separated by a 21-day washout period

Participants in this arm will first consume placebo for six weeks and then muscadine wine polyphenol for another six weeks. The two phases are separated by a 21-day washout period

Outcomes

Primary Outcome Measures

Change from baseline cognitive performance score after intervention/placebo
Participants will complete the NIH Toolbox cognitive battery. The test battery incorporates multiple tests that assess various aspects of cognitive performance. The list of tests and the function they measure are the following.1. Flanker inhibitory control and attention test (executive function): scoring is based on a combination of accuracy and reaction time. A 2-vector scoring method is employed that uses accuracy and reaction time, where each of these vectors ranges in value between 0 and 5, and the computed score, combining each vector score, ranges in value 0-10. The higher the score the better the performance. 2. Dimensional Change Card Sort (cognitive flexibility): scoring is the same as Flanker's test.
Change from baseline cognitive performance score after intervention/placebo - continued
3. Picture Sequence Test (episodic memory): Item Response Theory (IRT) is used to score this test. score known as a theta score is calculated for each participant; it represents the relative overall ability or performance of the participant. A theta score is very similar to a z-score, which is a statistic with a mean of zero and a standard deviation of one. The higher the score, the better the performance. 4. List Sorting Test (working memory: scored by summing the total number of items correctly recalled and sequenced on the tests, which can range from 0-26. 5. Pattern and Comparison Test (processing speed): The participant's raw score is the number of items answered correctly in 85 seconds of response time, with a range of 0-130. higher score means better performance. Both individual test scores and composite scores will be compared to baseline score
Change from baseline cognitive performance score after intervention/placebo - continued
6. Rey's Auditory Verbal Learning Test assesses immediate and delayed (30min) recall of a given list of words that is repeated 5 times. The number of correct words recalled and intrusion words (extraneous word offered by the participant that does not appear on the list) are recorded for scoring
Change from baseline monoamine oxidase (MAOs) activity
Blood samples will be drawn immediately after the completion test battery. Blood plasma level of monoamine oxidase (MAOs) activity will be determined using the Amplex Red Monoamine Oxidase Assay Kit to assess the inhibitory effects of muscadine wine/juice on MAOs.
Change from baseline neurotransmitters
Plasma levels of acetylcholine, dopamine, melatonin, serotonin, epinephrine, and γ-aminobutyric acid (GABA) will be quantified using the targeted metabolomic method on UHPLC-MS/MS
Change from baseline brain-derived neurotrophic factors
plasma BDNF will be measured using ELISA
Change from baseline cortisol, TNF-α, high sensitivity C-reactive protein, and LPS binding protein
Plasma levels will be measured using ELISA

Secondary Outcome Measures

Change from baseline mood and anxiety score after intervention/placebo
Participants will complete the NIH Toolbox emotion battery. The test battery include two self-report measure, Positive affect survey (assess mood): 5-point scale with options ranging from "not at all" to "very much." higher scores are indicative of more positive affect Fear-Affect Survey (assess anxiety): 5-point scale with options ranging from "never" to "always." higher scores are indicative of more feelings of fear and anxiety
Change from baseline depression score after intervention/placebo
Depression score will be assessed with Beck's Depression inventory. The questionnaire consists of 21 items with a four point scale ranges between 0-3. The higher the total score the more severe the depression.
Change from baseline pro-inflammatory cytokines
Inflammatory response will be evaluated by measuring the plasma level of pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha using Elisa Kits

Full Information

First Posted
September 12, 2022
Last Updated
August 31, 2023
Sponsor
University of Florida
search

1. Study Identification

Unique Protocol Identification Number
NCT05541887
Brief Title
Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health
Official Title
Acute and Chronic Impacts of Muscadine Wine Polyphenols on Cognition, Memory, Mood, and Anxiety in Adults Over 50 Years of Age
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 30, 2023 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Florida

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Previous studies have shown that polyphenol-rich foods can positively affect cognitive functions, memory, and mood in humans. We hypothesize that both acute and chronic intake of muscadine wine polyphenols will improve cognitive performance and mood through regulating the HPA axis, alleviating inflammation and oxidative stress, and/or inhibiting monoamine oxidase activities
Detailed Description
Although the exact biological mechanisms for depression and Alzheimer's Disease are not fully understood, it's believed that they are caused by a combination of factors. An increasing amount of scientific research has proposed several possible pathophysiologies linking depression and AD. For example, increased production of pro-inflammatory cytokines in the nervous system, oxidative stress induced by chronic inflammation leads to dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, and disturbance in the brain-derived neurotrophic factor signal pathway. Polyphenol has been well recognized for its antioxidant and anti-inflammatory properties. Previous studies have shown that polyphenol-rich food such as concord grape juice, blueberries, blackcurrants, and green oats positively affect cognition, memory, and mood in humans. However, no one has examined the effects of muscadine wine polyphenol on cognitive and mental health. In addition, if they do have effects, through what mechanism? This clinical trial will allow us to investigate the questions raised. We hypothesize that intake of muscadine wine polyphenols enhances cognition and memory and improve depression and anxiety in healthy adults over 50 year-old via regulating the HPA axis, alleviating inflammation and oxidative stress, and/or inhibiting monoamine oxidase activities. The research will provide the first clinical evidence of how muscadine wine polyphenols affect the brain and mental health.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognitive Performance, Memory, Mood, Anxiety

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention-Placebo
Arm Type
Active Comparator
Arm Description
Participants in this arm will consume muscadine wine polyphenol for six weeks and then placebo for another six weeks. The two phases are separated by a 21-day washout period
Arm Title
Placebo-Intervention
Arm Type
Active Comparator
Arm Description
Participants in this arm will first consume placebo for six weeks and then muscadine wine polyphenol for another six weeks. The two phases are separated by a 21-day washout period
Intervention Type
Other
Intervention Name(s)
Muscadine Wine Polyphenol
Other Intervention Name(s)
Dealcoholized Muscadine Wine
Intervention Description
dealcoholized muscadine wine with alcohol content <0.5%
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention
Primary Outcome Measure Information:
Title
Change from baseline cognitive performance score after intervention/placebo
Description
Participants will complete the NIH Toolbox cognitive battery. The test battery incorporates multiple tests that assess various aspects of cognitive performance. The list of tests and the function they measure are the following.1. Flanker inhibitory control and attention test (executive function): scoring is based on a combination of accuracy and reaction time. A 2-vector scoring method is employed that uses accuracy and reaction time, where each of these vectors ranges in value between 0 and 5, and the computed score, combining each vector score, ranges in value 0-10. The higher the score the better the performance. 2. Dimensional Change Card Sort (cognitive flexibility): scoring is the same as Flanker's test.
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Title
Change from baseline cognitive performance score after intervention/placebo - continued
Description
3. Picture Sequence Test (episodic memory): Item Response Theory (IRT) is used to score this test. score known as a theta score is calculated for each participant; it represents the relative overall ability or performance of the participant. A theta score is very similar to a z-score, which is a statistic with a mean of zero and a standard deviation of one. The higher the score, the better the performance. 4. List Sorting Test (working memory: scored by summing the total number of items correctly recalled and sequenced on the tests, which can range from 0-26. 5. Pattern and Comparison Test (processing speed): The participant's raw score is the number of items answered correctly in 85 seconds of response time, with a range of 0-130. higher score means better performance. Both individual test scores and composite scores will be compared to baseline score
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Title
Change from baseline cognitive performance score after intervention/placebo - continued
Description
6. Rey's Auditory Verbal Learning Test assesses immediate and delayed (30min) recall of a given list of words that is repeated 5 times. The number of correct words recalled and intrusion words (extraneous word offered by the participant that does not appear on the list) are recorded for scoring
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Title
Change from baseline monoamine oxidase (MAOs) activity
Description
Blood samples will be drawn immediately after the completion test battery. Blood plasma level of monoamine oxidase (MAOs) activity will be determined using the Amplex Red Monoamine Oxidase Assay Kit to assess the inhibitory effects of muscadine wine/juice on MAOs.
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Title
Change from baseline neurotransmitters
Description
Plasma levels of acetylcholine, dopamine, melatonin, serotonin, epinephrine, and γ-aminobutyric acid (GABA) will be quantified using the targeted metabolomic method on UHPLC-MS/MS
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Title
Change from baseline brain-derived neurotrophic factors
Description
plasma BDNF will be measured using ELISA
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Title
Change from baseline cortisol, TNF-α, high sensitivity C-reactive protein, and LPS binding protein
Description
Plasma levels will be measured using ELISA
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Secondary Outcome Measure Information:
Title
Change from baseline mood and anxiety score after intervention/placebo
Description
Participants will complete the NIH Toolbox emotion battery. The test battery include two self-report measure, Positive affect survey (assess mood): 5-point scale with options ranging from "not at all" to "very much." higher scores are indicative of more positive affect Fear-Affect Survey (assess anxiety): 5-point scale with options ranging from "never" to "always." higher scores are indicative of more feelings of fear and anxiety
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Title
Change from baseline depression score after intervention/placebo
Description
Depression score will be assessed with Beck's Depression inventory. The questionnaire consists of 21 items with a four point scale ranges between 0-3. The higher the total score the more severe the depression.
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)
Title
Change from baseline pro-inflammatory cytokines
Description
Inflammatory response will be evaluated by measuring the plasma level of pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha using Elisa Kits
Time Frame
Baseline, acute (4-hour post single dose), chronic (end of six week)

10. Eligibility

Sex
All
Gender Based
Yes
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy BMI (18.5-29.9) Body weight ≥110 pounds Exclusion Criteria: Pregnancy Breast-feeding Smokers Diabetic Heavy drinkers Subjective but not clinically diagnosed cognitive impairment (Montreal cognitive assessment score <26), Inability to understand the cognitive function tasks Intake of medication that might influence the outcome of the study (e.g. psychostimulant) cannabis product user Clinically diagnosed mental illnesses Cardiovascular and neurological disorders Uncontrolled hypertension
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kylee Mai
Phone
479-203-8170
Email
cmai1@ufl.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Liwei Gu, PhD
Email
Lgu@ufl.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Liwei Gu, PhD
Organizational Affiliation
University of Florida
Official's Role
Principal Investigator
Facility Information:
Facility Name
Food Science and human nutrition department at University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kylee Mai
Phone
479-203-8170
Email
cmai1@ufl.edu
First Name & Middle Initial & Last Name & Degree
Liwei Gu, PhD
Email
Lgu@ufl.edu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29184215
Citation
Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, Takahashi A, Flanigan ME, Aleyasin H, LeClair KB, Janssen WG, Labonte B, Parise EM, Lorsch ZS, Golden SA, Heshmati M, Tamminga C, Turecki G, Campbell M, Fayad ZA, Tang CY, Merad M, Russo SJ. Social stress induces neurovascular pathology promoting depression. Nat Neurosci. 2017 Dec;20(12):1752-1760. doi: 10.1038/s41593-017-0010-3. Epub 2017 Nov 13.
Results Reference
background
PubMed Identifier
25806005
Citation
Du X, Pang TY. Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases? Front Psychiatry. 2015 Mar 9;6:32. doi: 10.3389/fpsyt.2015.00032. eCollection 2015.
Results Reference
background
PubMed Identifier
28429081
Citation
Haskell-Ramsay CF, Stuart RC, Okello EJ, Watson AW. Cognitive and mood improvements following acute supplementation with purple grape juice in healthy young adults. Eur J Nutr. 2017 Dec;56(8):2621-2631. doi: 10.1007/s00394-017-1454-7. Epub 2017 Apr 20. Erratum In: Eur J Nutr. 2017 Oct 6;:
Results Reference
background
PubMed Identifier
26864371
Citation
Lamport DJ, Lawton CL, Merat N, Jamson H, Myrissa K, Hofman D, Chadwick HK, Quadt F, Wightman JD, Dye L. Concord grape juice, cognitive function, and driving performance: a 12-wk, placebo-controlled, randomized crossover trial in mothers of preteen children. Am J Clin Nutr. 2016 Mar;103(3):775-83. doi: 10.3945/ajcn.115.114553. Epub 2016 Feb 10.
Results Reference
background
PubMed Identifier
26437830
Citation
Whyte AR, Schafer G, Williams CM. Cognitive effects following acute wild blueberry supplementation in 7- to 10-year-old children. Eur J Nutr. 2016 Sep;55(6):2151-62. doi: 10.1007/s00394-015-1029-4. Epub 2015 Oct 5.
Results Reference
background
Citation
Watson AW, Haskell-Ramsay CF, Kennedy DO, Cooney JM, Trower T, Scheepens A. Acute supplementation with blackcurrant extracts modulates cognitive functioning and inhibits monoamine oxidase-B in healthy young adults. Journal of Functional Food. 2015 Aug;17:524-539. doi:10.1016/j.jff.2015.06.005
Results Reference
background
PubMed Identifier
32485993
Citation
Kennedy DO, Bonnlander B, Lang SC, Pischel I, Forster J, Khan J, Jackson PA, Wightman EL. Acute and Chronic Effects of Green Oat (Avena sativa) Extract on Cognitive Function and Mood during a Laboratory Stressor in Healthy Adults: A Randomised, Double-Blind, Placebo-Controlled Study in Healthy Humans. Nutrients. 2020 May 29;12(6):1598. doi: 10.3390/nu12061598.
Results Reference
background
PubMed Identifier
23009399
Citation
Bandaruk Y, Mukai R, Kawamura T, Nemoto H, Terao J. Evaluation of the inhibitory effects of quercetin-related flavonoids and tea catechins on the monoamine oxidase-A reaction in mouse brain mitochondria. J Agric Food Chem. 2012 Oct 17;60(41):10270-7. doi: 10.1021/jf303055b. Epub 2012 Oct 8.
Results Reference
background
PubMed Identifier
21964320
Citation
Zhu WL, Shi HS, Wei YM, Wang SJ, Sun CY, Ding ZB, Lu L. Green tea polyphenols produce antidepressant-like effects in adult mice. Pharmacol Res. 2012 Jan;65(1):74-80. doi: 10.1016/j.phrs.2011.09.007. Epub 2011 Sep 22.
Results Reference
background
PubMed Identifier
33054666
Citation
Olasehinde TA, Oyeleye SI, Ibeji CU, Oboh G. Beetroot supplemented diet exhibit anti-amnesic effect via modulation of cholinesterases, purinergic enzymes, monoamine oxidase and attenuation of redox imbalance in the brain of scopolamine treated male rats. Nutr Neurosci. 2022 May;25(5):1011-1025. doi: 10.1080/1028415X.2020.1831260. Epub 2020 Oct 15.
Results Reference
background

Learn more about this trial

Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health

We'll reach out to this number within 24 hrs